Treatment of minimal residual disease in acute leukemia--focus on immunotherapeutic options.
D000208:Acute Disease; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D006086:Graft vs Host Disease / Q000517:prevention & control; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D006912:Hydroxyquinolines / Q000627:therapeutic use; D007167:Immunotherapy; D007372:Interferons / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D007938:Leukemia / Q000628:therapy*; D008264:Macrophages / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D006912:Hydroxyquinolines; D007376:Interleukin-2; C045282:roquinimex; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D007372:Interferons